Varian, Inc. Reports Fourth Quarter 20...($277478 Adjustments: Acquisi...),Health

Date:11/4/2009

$277,478 Adjustments: Acquisition-related intangible amortization (194) (586) (1,118) (1,825) Costs related to pending acquisition by Agilent (9,155) - (9,155) - Restructuring and other related costs (232) (273) (4,754) (2,581) -------- -------- -------- -------- As adjusted $ 55,063 $ 74,239 $224,255 $273,072 ======== ======== ======== ======== Research and Development U.S. GAAP as reported $ 13,448 $ 17,921 $ 56,425 $ 71,810 Adjustments: Restructuring and other related costs 246 (501) (842) (1,254) -------- -------- -------- -------- As adjusted $ 13,694 $ 17,420 $ 55,583 $ 70,556 ======== ======== ======== ======== Purchased In-Process Research and Development U.S. GAAP as reported $ - $ 215 $ - $ 1,703 Adjustments: Acquisition-related in- process research and development charge - (215) - (1,703) -------- -------- -------- -------- As adjusted $ - $ - $ - $ - ======== ======== ======== ========

                      VARIAN, INC. AND SUBSIDIARY COMPANIES
                RECONCILIATION OF GAAP TO ADJUSTED RESULTS - ACTUAL
                        UNAUDITED RESULTS OF OPERATIONS
                      (In thousands, except per share data)
               Fourth Quarter FY 2009 and Fourth Quarter FY 2008
                                      and
                    Full Year FY 2009 and Full Year FY 2008

                                   F
'/>"/>
SOURCE  Varian, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
Related medicine technology :

1. Varian, Inc. to Release Fourth Quarter and Full Fiscal Year 2009 Financial Results
2. Varian, Inc. Delivers a Productivity Increase of Up to 100% With Its 710-ES Series ICP-OES
3. 96-Well Filtration Plate From Varian, Inc. Improves Sensitivity and Precision for Trace Bio-Analysis by LC/MS
4. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
5. Medivation Reports Third Quarter 2009 Financial Results and Provides Corporate Update
6. Cambrex Reports Third Quarter 2009 Results
7. Regeneron Reports Third Quarter 2009 Financial and Operating Results
8. Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C
9. Uroplasty Reports Results for Second Quarter FY2010
10. Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD
11. Mettler-Toledo International Inc. Reports Third Quarter 2009 Results